A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2015
At a glance
- Drugs AZD 3241 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 01 Jun 2013 Status changed from active, no longer recruiting to completed.
- 08 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Dec 2012 Planned end date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.